N/A N=22 Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis
Gastric Stasis
Primary: Percentage of Slow Wave Entrainment — 72; 70; 84; 78 percentage of slow waves entrainment
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
Diabetic Gastroparesis
Primary: Hypoglycemic Episodes — 1.9; 2.2 event rate per person-week — p=<0.0001
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
Phase 2 N=25 Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Gastroparesis
Primary: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate — 267.12; 283.09; 221.74 kPCD/minutes — p=<0.05
Phase 3 N=130 Nortriptyline for Idiopathic Gastroparesis
Idiopathic Gastroparesis
Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86
Early Phase 1 N=14 Pioglitazone for Idiopathic Gastroparesis
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
N/A N=32 Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
Gastroparesis
Primary: Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index. — 6.8; 10.1 units on a scale
Phase 2 N=21 A Study of CNSA-001 in Women With Diabetic Gastroparesis
Gastroparesis
Primary: Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14 — 293.5; 345.6; 1.3; 2.0 mL — p=0.9030
Phase 2 N=114 A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Gastroparesis
Primary: Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week…
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
Phase 2 N=152 Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
Gastroparesis
Primary: Change From Baseline in Average Nausea Severity — -1.25; -0.73 score on a scale (change from baseline) — p=.0099
Phase 3 N=14 Sancuso® for Gastroparesis: An Open Label Study.
Gastroparesis
Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01
Phase 2 N=96 Buspirone for Early Satiety and Symptoms of Gastroparesis
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
Phase 2 N=287 Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis
Gastroparesis · Diabetic Gastroparesis · Diabetes
Primary: The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)…
Phase 2 N=393 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
Diabetes Mellitus · Diabetes Mellitus Complications · Gastroparesis
Primary: Change From Baseline to Week 12 in Weekly Vomiting Episodes — 5.7; 7.7; 6.9; 4.8 vomiting episodes per week — p=0.36
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Phase 2 N=20 A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
Gastroparesis · Diabetes Mellitus
Primary: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration — 1.6; 1.5; 10.6; 1.5 ng/mL — p=0.0002
Phase 4 N=21 U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
Type 2 Diabetes · Insulin Resistance
Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
Phase 2 N=36 Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
Phase 2 N=242 A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Change From Baseline in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD) Composite Score at Week…
Phase 2 N=161 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Change From Baseline of Nausea Severity Score — -3.55; -3.65; -3.43; -2.83 units on a scale — p=0.1350
Phase 3 N=205 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
Diabetic Gastroparesis
Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.925; -0.896 score on a scale — p=0.881
Phase 2 N=16 Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
Phase 2 N=7 Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
Hypoglycemia · Complications of Bariatric Procedures
Primary: Detection/Notification of Hypoglycemia — 9 successful events
Phase 3 N=53 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
Diabetic Gastroparesis
Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.751; -0.657 score on a scale — p=0.597
Phase 2 N=57 A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastroparesis
Primary: Dose-normalized Levodopa (L-DOPA) Area Under the Plasma Concentration-time Curve From Zero to 4 Hours AUC(0-4) at Baseline — 24.13; 24.81…
Phase 4 N=12 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis
Gastroparesis · Gastroesophageal Reflux Disease
Primary: Time to Maximal Omeprazole Concentration (Tmax) — 32; 97 minutes — p=< 0.01